

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Hansoh Pharmaceutical Group Company Limited

### 翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

## VOLUNTARY ANNOUNCEMENT

### CLINICAL TRIAL APPROVAL OF ORAL SMALL MOLECULE 3CL PROTEASE INHIBITOR “HS-10517 TABLETS” AGAINST SARS-CoV-2

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that “HS-10517 tablets”, a Category 1 innovative drug and oral small molecule 3CL protease inhibitor against SARS-CoV-2, for which the Group holds license from Beijing Huayi Health Drug Discovery Institute\* (北京華益健康藥物研究中心) (also known as the Global Health Drug Discovery Institute, (“**GHDDI**”)), has been granted a clinical trial approval issued by the National Medical Products Administration of the People’s Republic of China, and is intended to be used for the treatment of adult patients with mild to moderate SARS-CoV-2 infection.

As disclosed in the announcement of the Company dated August 22, 2022, Hansoh (Shanghai) Healthtech Company Limited\* (翰森(上海)健康科技有限公司), a subsidiary of the Company, obtained an exclusive license from GHDDI to develop, manufacture and commercialize the anti-SARS-CoV-2 new drug candidate GDI-4405 series worldwide.

#### ABOUT HS-10517

HS-10517 (belong to GDI-4405 series) is an oral small molecule 3CL protease inhibitor against SARS-CoV-2. HS-10517 exhibits high potent antiviral activity on SARS-CoV-2 delta and omicron variants.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, January 17, 2023

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* For identification purposes only